Skip to main content

What the FDA labels say about taking them together

Efavirenz and sofosbuvir/velpatasvir

Efavirenz's FDA label of March 31, 2024 names sofosbuvir/velpatasvir in its drug interactions section, and sofosbuvir/velpatasvir's label names efavirenz too. The sofosbuvir/velpatasvir label: “Coadministration of EPCLUSA with efavirenz-containing regimens is not recommended.”

Check it at the source: the efavirenz FDA label on DailyMed (effective March 31, 2024, Cipla USA Inc.); the sofosbuvir/velpatasvir FDA label on DailyMed (effective June 5, 2024, Gilead Sciences, Inc.).

What does the efavirenz label say about sofosbuvir/velpatasvir?

Efavirenz label, drug interactions

Velpatasvir/ Sofosbuvir ↓ velpatasvir Coadministration of efavirenz and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir.

Source: FDA drug label (Efavirenz), Cipla USA Inc., effective March 31, 2024 (SPL set 92603fa5-7a2c-4bfb-9a70-aadb4fba952c), via openFDA; the full label on DailyMed

What does the sofosbuvir/velpatasvir label say about efavirenz?

Sofosbuvir/velpatasvir label, drug interactions

Concomitant Drug Class/Drug Name: HIV Antiretrovirals: efavirenz; Effect on Concentration ↓ = decrease, ↑ = increase.: ↓ velpatasvir; Clinical Effect/Recommendation: Coadministration of EPCLUSA with efavirenz-containing regimens is not recommended.

Source: FDA drug label (Epclusa), Gilead Sciences, Inc., effective June 5, 2024 (SPL set 7f30631a-ee3b-4cfe-866b-964df3f0a44f), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

5Efavirenz generic labelers
0Sofosbuvir/velpatasvir generic labelers
EfavirenzSofosbuvir/velpatasvir
Labeled forHIVHepatitis C
Boxed warningNoYes
Pharmacy cost (NADAC)$1.28 per tablet 600 mg tablet$278.03 per unit 400-100
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?